Search Results | Blood | American Society of Hematology

1-20 of 72

2 3 4

Sort by

Sort Order Select

Journal Articles

Subsequent Anti-Myeloma Therapy after Idecabtagene Vicleucel (ide-cel, bb2121) Treatment in Patients with Relapsed/Refractory Multiple Myeloma from the KarMMa Study

Paula Rodriguez-Otero, Jesús F. San-Miguel, Larry D. Anderson, Jr., Sagar Lonial, Anna Truppel-Hartmann, Jill Sanford, Everton Rowe, Timothy B. Campbell, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 2743.

DOI: https://doi.org/10.1182/blood-2021-147990

Published: 2021

Journal Articles

Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?

Blood (2021) 138 (Supplement 1): 2746.

DOI: https://doi.org/10.1182/blood-2021-152681

Published: 2021

Journal Articles

Updated Health-Related Quality of Life Results from the KarMMa Clinical Study in Patients with Relapsed and Refractory Multiple Myeloma Treated with the B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Idecabtagene Vicleucel (ide-cel, bb2121)

Michel Delforge, Nina Shah, Paula Rodríguez-Otero, Julia Braverman, Devender Dhanda, Ling Shi, Shien Guo, Peiwen Yu, Weiqin Liao, Timothy B. Campbell, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 2835.

DOI: https://doi.org/10.1182/blood-2021-145155

Published: 2021

Journal Articles

Results from a Pilot Study of ARI0002h, an Academic BCMA-Directed CAR-T Cell Therapy with Fractionated Initial Infusion and Booster Dose in Patients with Relapsed and/or Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2837.

DOI: https://doi.org/10.1182/blood-2021-147188

Published: 2021

Journal Articles

Matching-Adjusted Indirect Comparisons of Efficacy Outcomes in Patients with Relapsed and Refractory Multiple Myeloma for Idecabtagene Vicleucel (KarMMa) Versus Selinexor Plus Dexamethasone (STORM Part 2) and Belantamab Mafodontin (DREAMM-2): Updated Analysis with Longer Follow-up

Paula Rodríguez-Otero, Ali Mojebi, Dieter Ayers, Devender Dhanda, James Farrell, Faith E. Davies, Michel Delforge, Katja Weisel, Kevin Towle, Tom Marshall, Clyde Caisip, Shannon Cope

Blood (2021) 138 (Supplement 1): 1978.

DOI: https://doi.org/10.1182/blood-2021-145321

Published: 2021

Journal Articles

CAR Density Influences Antitumoral Efficacy of BCMA CAR-T Cells and Correlates with Clinical Outcome

Blood (2021) 138 (Supplement 1): 735.

DOI: https://doi.org/10.1182/blood-2021-148578

Published: 2021

Journal Articles

LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy

Blood (2021) 138 (Supplement 1): 3057.

DOI: https://doi.org/10.1182/blood-2021-146188

Published: 2021

Journal Articles

Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies

Blood (2021) 138 (Supplement 1): 541.

DOI: https://doi.org/10.1182/blood-2021-150092

Published: 2021

Journal Articles

Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Blood (2021) 138 (Supplement 1): 552.

DOI: https://doi.org/10.1182/blood-2021-148281

Published: 2021

Journal Articles

Idecabtagene Vicleucel (ide-cel, bb2121), a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy: Qualitative Analyses of Post-Treatment Interviews (Months 6-24) for Patients with Relapsed and Refractory Multiple Myeloma in the Karmma Clinical Trial

Nina Shah, Michel Delforge, Paula Rodríguez-Otero, Olga Moshkovich, Julia Braverman, Devender Dhanda, Sally Lanar, Jennifer Devlen, Matthew Miera, Heather Gerould, Timothy B. Campbell, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 3041.

DOI: https://doi.org/10.1182/blood-2021-145166

Published: 2021

Journal Articles

Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study

Blood (2021) 138 (Supplement 1): 157.

DOI: https://doi.org/10.1182/blood-2021-147983

Published: 2021

Journal Articles

Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Amrita Y. Krishnan, Monique C. Minnema, Jesús G. Berdeja, Albert Oriol, Niels W.C.J. van de Donk, Paula Rodriguez-Otero, Elham Askari, Maria-Victoria Mateos, Luciano J. Costa, Raluca I. Verona, Xuewen Ma, Suzette Girgis, Shiyi Yang, Brandi W. Hilder, Jeffery Russell, Jenna D. Goldberg, Ajai Chari

Blood (2021) 138 (Supplement 1): 158.

DOI: https://doi.org/10.1182/blood-2021-146868

Published: 2021

Journal Articles

KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Noopur S. Raje, Jesús G. Berdeja, Paula Rodriguez-Otero, Damian J. Green, Sundar Jagannath, Sagar Lonial, Adrianna Gipson, Andrea Caia, Nathan Martin, Zhihong Yang, Gianfranco Pittari, Maria-Victoria Mateos

Blood (2021) 138 (Supplement 1): 4830.

DOI: https://doi.org/10.1182/blood-2021-147412

Published: 2021

Journal Articles

Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 161.

DOI: https://doi.org/10.1182/blood-2021-148813

Published: 2021

Journal Articles

Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study

Blood (2021) 138 (Supplement 1): 1647.

DOI: https://doi.org/10.1182/blood-2021-148723

Published: 2021

Journal Articles

Progression-Free Survival Outcomes By Response Status for Bortezomib, Melphalan, and Prednisone with or without Daratumumab in Newly Diagnosed Multiple Myeloma: Pooled Subgroup Analysis of Octans and Alcyone

Blood (2021) 138 (Supplement 1): 1648.

DOI: https://doi.org/10.1182/blood-2021-148937

Published: 2021

Journal Articles

Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone

Blood (2021) 138 (Supplement 1): 1661.

DOI: https://doi.org/10.1182/blood-2021-146974

Published: 2021

Journal Articles

Selinexor in Combination with Daratumumab-Bortezomib and Dexamethasone for the Treatment of Relapse or Refractory Multiple Myeloma: Initial Results of the Phase 2, Open-Label, Multicenter GEM-Selibordara Study

Paula Rodríguez-Otero, Veronica Gonzalez De La Calle, Anna Sureda, Felipe De Arriba, Marta Reinoso Segura, Paz Ribas, Ana Pilar Gonzalez, Yolanda Gonzalez-Montes, Albert Oriol, Joaquín Martínez-López, Marta Sonia Gonzalez, Miguel T Hernández, Maialen Sirvent, Joan Bladé Creixenti, Juan Jose Lahuerta, Jesús F. San-Miguel, Maria-Victoria Mateos

Blood (2021) 138 (Supplement 1): 1677.

DOI: https://doi.org/10.1182/blood-2021-147725

Published: 2021

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Blood (2021) 138 (Supplement 1): 1829.

DOI: https://doi.org/10.1182/blood-2021-148423

Published: 2021

Journal Articles

Predictive Biomarkers of Response to Venetoclax in Combination with Cobimetinib in Relapsed/Refractory Multiple Myeloma (RRMM)

Aparna Raval, Habib Hamidi, Olivia Hwang, Cherie Green, Catarina Maia, Marta Lasa, Maika Onishi, Paula Rodriguez-Otero, Jesús F. San-Miguel, Jorge D. Gallo, Bruno Paiva, PhD, Fredrik Schjesvold, MDPhD

Blood (2020) 136 (Supplement 1): 30–31.

DOI: https://doi.org/10.1182/blood-2020-134910

Published: 2020

2 3 4

NARROW

Subsequent Anti-Myeloma Therapy after Idecabtagene Vicleucel (ide-cel, bb2121) Treatment in Patients with Relapsed/Refractory Multiple Myeloma from the KarMMa Study

Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?

Updated Health-Related Quality of Life Results from the KarMMa Clinical Study in Patients with Relapsed and Refractory Multiple Myeloma Treated with the B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Idecabtagene Vicleucel (ide-cel, bb2121)

Results from a Pilot Study of ARI0002h, an Academic BCMA-Directed CAR-T Cell Therapy with Fractionated Initial Infusion and Booster Dose in Patients with Relapsed and/or Refractory Multiple Myeloma

Matching-Adjusted Indirect Comparisons of Efficacy Outcomes in Patients with Relapsed and Refractory Multiple Myeloma for Idecabtagene Vicleucel (KarMMa) Versus Selinexor Plus Dexamethasone (STORM Part 2) and Belantamab Mafodontin (DREAMM-2): Updated Analysis with Longer Follow-up

CAR Density Influences Antitumoral Efficacy of BCMA CAR-T Cells and Correlates with Clinical Outcome

LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy

Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies

Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Idecabtagene Vicleucel (ide-cel, bb2121), a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy: Qualitative Analyses of Post-Treatment Interviews (Months 6-24) for Patients with Relapsed and Refractory Multiple Myeloma in the Karmma Clinical Trial

Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study

Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma

Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study

Progression-Free Survival Outcomes By Response Status for Bortezomib, Melphalan, and Prednisone with or without Daratumumab in Newly Diagnosed Multiple Myeloma: Pooled Subgroup Analysis of Octans and Alcyone

Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone

Selinexor in Combination with Daratumumab-Bortezomib and Dexamethasone for the Treatment of Relapse or Refractory Multiple Myeloma: Initial Results of the Phase 2, Open-Label, Multicenter GEM-Selibordara Study

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Predictive Biomarkers of Response to Venetoclax in Combination with Cobimetinib in Relapsed/Refractory Multiple Myeloma (RRMM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only